Is Your House Making You Sneeze; A Review of Perennial Allergies
This continuing education activity is administered by the National Association of Pediatric Nurse Practitioners (NAPNAP) as an Agency providing continuing education credit. Individuals who complete this program and earn a 70% or higher score on the post test will be awarded 1.0 NAPNAP contact hours, of which 0.25 is pharmacology content.
This course was supported by an educational grant from Merck.
IMPORTANT: This continuing education activity is FREE to NAPNAP Members. You must be logged in using your NAPNAP Member ID # and Password to be recognized as a Member of NAPNAP. If you are a current member of NAPNAP, and you are being asked to purchase this activity, please contact the NAPNAP National Office at (877) 662-7627 to request assistance prior to entering any payment information.
Participants are forbidden to reproduce, republish, redistribute, or resell this course in any other form. For copyright-related questions, please email your question to: firstname.lastname@example.org
Copyright 2016 © by National Association of Pediatric Nurse Practitioners (NAPNAP).
Pediatric-focused advanced practice registered nurses.
At the conclusion of this live webinar, participants will be able to:
1. Identify common indoor aeroallergens.
2. Describe environmental controls to reduce allergen exposure.
3. List medications available to treat allergic rhinitis.
Jodi A. Shroba, MSN, APRN, CPNP
Jodi Shroba is a Pediatric Nurse Practitioner in the Allergy, Asthma and Immunology Clinic at Children's Mercy Hospital in Kansas City, MO. She has spoken both locally and nationally on Allergic Rhinitis, including presentations at the Missouri State School Nurse Conference and the NAPNAP and ACAAI National Conferences.
Faculty Disclosure: Ms. Shroba is a paid speaker for Meda Pharmaceutical, and she lectures on their products; Aerospan (asthma medication) and Dymista (nasal corticosteroid/antihistamine nasal spray). In this webinar, she will discuss all nasal sprays and there will be no bias towards any specific drug.
FDA Disclosure: Ms. Shroba will discuss some antihistamines used twice a day despite a once a day indication.
- 1.00 Contact hours